Martin H. Bolli
Drug Discovery Chemistry
Actelion Pharmaceuticals Ltd.
Gewerbestrasse 16
CH-4123 Allschwil
Switzerland
Name/email consistency: high
- Synthetic sphingosine 1-phosphate receptor modulators--opportunities and potential pitfalls. Bolli, M.H., Lescop, C., Nayler, O. Curr. Top. Med. Chem (2011)
- 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. Bolli, M.H., Abele, S., Binkert, C., Bravo, R., Buchmann, S., Bur, D., Gatfield, J., Hess, P., Kohl, C., Mangold, C., Mathys, B., Menyhart, K., Müller, C., Nayler, O., Scherz, M., Schmidt, G., Sippel, V., Steiner, B., Strasser, D., Treiber, A., Weller, T. J. Med. Chem. (2010)
- Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists. Bolli, M.H., Marfurt, J., Grisostomi, C., Boss, C., Binkert, C., Hess, P., Treiber, A., Thorin, E., Morrison, K., Buchmann, S., Bur, D., Ramuz, H., Clozel, M., Fischli, W., Weller, T. J. Med. Chem. (2004)
- The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists. Bolli, M.H., Boss, C., Clozel, M., Fischli, W., Hess, P., Weller, T. Bioorg. Med. Chem. Lett. (2003)
